PF-05280586 vs Rituximab-abbs (Truxima)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: CD20 · full Rheumatoid Arthritis pipeline
PF-05280586
Marketed by Pfizer
NCT01526057 · Phase 2 · completed
The 220-participant trial was randomized, quadruple-blind, and actively controlled with European- and US-sourced rituximab. The primary pharmacokinetic comparisons met the prespecified equivalence range for both peak concentration and total drug exposure, but these were surrogate measures rather than hard clinical outcomes, supporting a moderate evidence grade.
Reported efficacy
Maximum Serum Concentration (Cmax) of Rituximab (Predose (Day 1) and 3, 4.25 (immediately before 1st infusion end), 72, 168, 335 (Day 15 within 1.5 hours before 2nd infusion), 337.5, 339.25 (Day 15 immediately before 2nd infusion end), 408, 504, 672, 1344, and 2016 hours after start of 1st infusion); AUC 0-inf of Rituximab (Predose (Day 1) and 3, 4.25 (immediately before 1st infusion end), 72, 168, 335 (Day 15 within 1.5 hours before 2nd infusion), 337.5, 339.25 (Day 15 immediately before 2nd infusion end), 408, 504, 672, 1344, and 2016 hours after start of 1st infusion): Maximum Serum Concentration (Cmax) of Rituximab (Predose (Day 1) and 3, 4.25 (immediately before 1st infusion end), 72, 168, 335 (Day 15 within 1.5 hours before 2nd infusion), 337.5, 339.25 (Day 15 immediately before 2nd infusion end), 408, 504, 672, 1344, and 2016 hours after start of 1st infusion): Rituximab-Pfizer 453 micrograms per milliliter (Standard Deviation 153) | Rituximab-EU 422 micrograms per milliliter (Standard Deviation 111) | Rituximab-US 430 micrograms per milliliter (Standard Deviation 163) (met)
Result source: NCT01526057
Rituximab-abbs (Truxima)
Marketed by Celltrion and partners
NCT02149121 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial with an adequately sized population (384 enrolled) that pre-specified formal equivalence margins for both its pharmacokinetic and its clinical disease-activity (DAS28-CRP) primary endpoints, and every comparison landed entirely within the required margin, meaning the biosimilar demonstrated therapeutic equivalence to the reference product on a validated hard clinical measure of rheumatoid arthritis activity, not just a proxy lab value.
Reported efficacy
Analysis of Serum AUC0-last of Rituximab During the 1st Course of the Main Study Period (Over the First 24 Weeks) (ANCOVA); Analysis of Serum AUC0-inf of Rituximab During the 1st Course of the Main Study Period (Over the First 24 Weeks) (ANCOVA) (at Week 24 of the Main Study Period); Analysis of Serum Cmax of Rituximab During the 1st Course of the Main Study Period (Over the First 24 Weeks) (ANCOVA) (at Week 24 of the Main Study Period); Analysis of Change From Baseline of DAS28 (CRP) at Week 24 (ANCOVA) (at Week 24 of the Main Study Period): Primary efficacy: DAS28-CRP change from baseline -2.11 with CT-P10 vs -2.10 with reference products; treatment difference -0.01 (90% CI -0.22 to 0.20), with an equivalence margin of ±0.50. Primary PK AUC0-last ratio: 97.07% (CT-P10/Rituxan; 90% CI 88.08% to 106.99%) and 94.18% (CT-P10/MabThera; 90% CI 85.40% to 103.86%). (met)
Result source: NCT02149121
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | PF-05280586 | Rituximab-abbs (Truxima) |
|---|---|---|
| ACR20 | 77.1% vs 90%vs Rituximab-EUNCT0164392818 other results
| —Not reported |
| ACR50 | 51.4% vs 30%vs Rituximab-EUNCT0164392818 other results
| —Not reported |
| ACR70 | 22.9% vs 10%vs Rituximab-EUNCT0164392818 other results
| —Not reported |
| DAS28-CRP remission | 45.7% vs 20%vs Rituximab-EUNCT0164392811 other results
| —Not reported |
| HAQ-DI, change | -0.4 vs -0.5vs RituximabNCT015260576 other results
| —Not reported |
| Modified Sharp score, change | —Not reported | —Not reported |
ACR20
- PF-05280586
- 77.1% vs 90%vs Rituximab-EUNCT01643928
18 other results
- 81.8% vs 90% NCT01643928
- 73.7% vs 90% NCT01643928
- 69.6% vs 77.4% NCT01643928
- 84.8% vs 77.4% NCT01643928
- 82.8% vs 77.4% NCT01643928
- 66.7% vs 71% NCT01643928
- 84.8% vs 71% NCT01643928
- 76.7% vs 71% NCT01643928
- 50% vs 59.4% NCT01643928
- 63.6% vs 59.4% NCT01643928
- 60% vs 59.4% NCT01643928
- 50% vs 60.3% NCT01526057
- 54.2% vs 62.2% NCT01526057
- 54.8% vs 67.6% NCT01526057
- 50.7% vs 70.3% NCT01526057
- 49.3% vs 60.8% NCT01526057
- 54.8% vs 56.8% NCT01526057
- 34.2% vs 33.8% NCT01526057
- Rituximab-abbs (Truxima)
- —Not reported
ACR50
- PF-05280586
- 51.4% vs 30%vs Rituximab-EUNCT01643928
18 other results
- 63.6% vs 30% NCT01643928
- 36.8% vs 30% NCT01643928
- 37.5% vs 41.9% NCT01643928
- 66.7% vs 41.9% NCT01643928
- 58.6% vs 41.9% NCT01643928
- 33.3% vs 51.6% NCT01643928
- 51.5% vs 51.6% NCT01643928
- 53.3% vs 51.6% NCT01643928
- 17.2% vs 28.1% NCT01643928
- 48.5% vs 28.1% NCT01643928
- 30% vs 28.1% NCT01643928
- 21% vs 38.1% NCT01526057
- 27.8% vs 37.8% NCT01526057
- 24.7% vs 36.5% NCT01526057
- 35.6% vs 40.5% NCT01526057
- 21.9% vs 32.4% NCT01526057
- 19.2% vs 16.2% NCT01526057
- 8.2% vs 5.4% NCT01526057
- Rituximab-abbs (Truxima)
- —Not reported
ACR70
- PF-05280586
- 22.9% vs 10%vs Rituximab-EUNCT01643928
18 other results
- 36.4% vs 10% NCT01643928
- 15.8% vs 10% NCT01643928
- 23.2% vs 32.3% NCT01643928
- 36.4% vs 32.3% NCT01643928
- 34.5% vs 32.3% NCT01643928
- 21.1% vs 22.6% NCT01643928
- 33.3% vs 22.6% NCT01643928
- 30% vs 22.6% NCT01643928
- 5.2% vs 12.5% NCT01643928
- 21.2% vs 12.5% NCT01643928
- 10% vs 12.5% NCT01643928
- 16.1% vs 17.5% NCT01526057
- 13.9% vs 23% NCT01526057
- 15.1% vs 18.9% NCT01526057
- 19.2% vs 28.4% NCT01526057
- 12.3% vs 17.6% NCT01526057
- 6.8% vs 6.8% NCT01526057
- 2.7% vs 2.7% NCT01526057
- Rituximab-abbs (Truxima)
- —Not reported
DAS28-CRP remission
- PF-05280586
- 45.7% vs 20%vs Rituximab-EUNCT01643928
11 other results
- 27.3% vs 20% NCT01643928
- 21.1% vs 20% NCT01643928
- 33.9% vs 46.7% NCT01643928
- 45.5% vs 46.7% NCT01643928
- 37.9% vs 46.7% NCT01643928
- 32.1% vs 38.7% NCT01643928
- 34.4% vs 38.7% NCT01643928
- 32.1% vs 38.7% NCT01643928
- 3.9% vs 10.7% NCT01643928
- 19.4% vs 10.7% NCT01643928
- 7.1% vs 10.7% NCT01643928
- Rituximab-abbs (Truxima)
- —Not reported
HAQ-DI, change
- PF-05280586
- -0.4 vs -0.5vs RituximabNCT01526057
6 other results
- -0.4 vs -0.6 NCT01526057
- -0.3 vs -0.6 NCT01526057
- -0.4 vs -0.6 NCT01526057
- -0.4 vs -0.5 NCT01526057
- -0.3 vs -0.3 NCT01526057
- -0.2 vs -0.2 NCT01526057
- Rituximab-abbs (Truxima)
- —Not reported
Modified Sharp score, change
- PF-05280586
- —Not reported
- Rituximab-abbs (Truxima)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. PF-05280586: 5 of 5 rows · Rituximab-abbs (Truxima): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | PF-05280586 | Rituximab-abbs (Truxima) |
|---|---|---|
| DAS28-CRP absolute change · score | -1.7 vs -2 Rituximab score @ 25wka,b,c,d NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2 | -2.7 vs -2.6 Rituxan score @ 48wka,b,c,d NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 |
| Dropout rate | 12.3%e NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2 show 12 more results—PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence 17.2%PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence 9.1%PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence 6.7%PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence | 13%CT-P10 (Main Study Period) NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 show 1 more result—CT-P10/CT-P10 (Extension Study Per NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 |
| Discontinued due to AEs | 4.1%e NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2 show 12 more results—PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence 3.4%PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence 0%PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence 6.7%PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence | 1.2%CT-P10 (Main Study Period) NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 show 1 more result—CT-P10/CT-P10 (Extension Study Per NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 |
| Serious AEs | 6.8%e NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2 show 12 more results6.1%PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence 12.9%PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence 13.3%PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence 6.7%PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence 3.4%PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence 3.4%PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence 6.9%PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence 11.1%PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence 8.3%PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence | 8.1%CT-P10 (Main Study Period) NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 show 1 more result3.3%CT-P10/CT-P10 (Extension Study Per NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 |
| Most frequent reported AEs | e upper respiratory tract infection 9.6% fatigue 6.8% hypertension 5.5% NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2 show 9 more resultsrheumatoid arthritis 9.1% vomiting 6.1% back pain 3% NCT01643928 · Phase na · registry result, not featured evidence rheumatoid arthritis 9.7% back pain 6.5% sinusitis 6.5% NCT01643928 · Phase na · registry result, not featured evidence rheumatoid arthritis 10% urinary tract infection 10% arthralgia 6.7% NCT01643928 · Phase na · registry result, not featured evidence diarrhoea 6.7% oropharyngeal pain 6.7% gastroenteritis 3.3% NCT01643928 · Phase na · registry result, not featured evidence diarrhoea 6.9% nausea 6.9% oropharyngeal pain 6.9% NCT01643928 · Phase na · registry result, not featured evidence upper respiratory tract infection 10.3% alanine aminotransferase increased 6.9% aspartate aminotransferase increased 6.9% NCT01643928 · Phase na · registry result, not featured evidence rheumatoid arthritis 6.9% urinary tract infection 6.9% fatigue 5.2% NCT01643928 · Phase na · registry result, not featured evidence rheumatoid arthritis 9.3% urinary tract infection 9.3% bronchitis 7.4% NCT01643928 · Phase na · registry result, not featured evidence bronchitis 10.4% rheumatoid arthritis 10.4% urinary tract infection 10.4% NCT01643928 · Phase na · registry result, not featured evidence | infusion-related reaction 20.5% upper respiratory tract infection 14.9% urinary tract infection 9.3% NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 show 1 more resultupper respiratory tract infection 8.2% urinary tract infection 6.6% infusion-related reaction 3.3% NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 |
Notes
- aTrial phases differ: Phase 2 versus Phase 3.
- bPopulation context differs: baseline_threshold differs (none recorded versus swollen_joint_count>=6).
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 25 weeks versus 48 weeks.
- ePopulation comparability has not been reviewed for 12 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
PF-05280586
show 18 more results
show 18 more results
show 18 more results
show 18 more results
show 6 more results
show 6 more results
show 6 more results
show 6 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
+ 102 further endpoints in the CSV export.
Rituximab-abbs (Truxima)
show 2 more results
Non-Hodgkin Lymphoma
Shared mechanism: CD20 · full Non-Hodgkin Lymphoma pipeline
PF-05280586
Marketed by Pfizer
NCT02213263 · Phase 3 · completed
The trial randomized 394 participants to PF-05280586 or active comparator MabThera and was double-blind. The primary endpoint was the clinical response rate at Week 26, and the prespecified equivalence margin was met because the 95% confidence interval for the response-rate difference (-4.16% to 13.47%) remained within the -16% to 16% limits.
Reported efficacy
Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26: Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26 (Week 26): Rituximab-EU 70.7 percentage of participants (95% CI 63.8 to 76.9) | PF-05280586 75.5 percentage of participants (95% CI 68.9 to 81.4) (met)
Result source: NCT02213263
Rituximab-abbs (Truxima)
Marketed by Celltrion and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Non-Hodgkin Lymphoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Rituximab-abbs (Truxima): no structured comparison results are available for Non-Hodgkin Lymphoma.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: PF-05280586's landscape · Rituximab-abbs (Truxima)'s landscape